Sangamo (SGMO) executive shares withheld to cover RSU tax obligations
Rhea-AI Filing Summary
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, had 1,630 shares of Common Stock surrendered to the company on May 25, 2026 for mandatory tax withholding tied to a restricted stock unit (RSU) vesting. The withholding used the issuer’s closing stock price of $0.1743 per share and is classified as a disposition to the issuer for reporting purposes, not an open-market trade. After this tax-withholding transaction, Davis directly holds 113,654 shares. The footnotes state this includes 3,031 shares from the May 25, 2026 vesting installment of a February 25, 2025 RSU grant, with an additional 32,633 RSU shares scheduled to vest in seven equal quarterly installments, subject to continued service under the 2018 equity incentive plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 1,630 | $0.1743 | $284.11 |
Footnotes (1)
- Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: 3,031 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 32,633 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.